FDA Recommends Pausing Use of J&J COVID-19 Vaccine After Reports of Blood Clots
CDC and FDA are reviewing data from reported cases of a rare type of blood clot in people that received the Johnson & Johnson COVID-19 vaccine.
FDA and the Centers for Disease Control (CDC) announced on April 13, 2021 that they are evaluating six cases in the United States of a rare and severe type of blood clot, cerebral venous sinus thrombosis (CVST), that occurred in women after they received the Johnson & Johnson (J&J) vaccine. The CVST clot was seen in combination with low levels of blood platelets and occurred in women ages 18–48. The symptoms appeared 6–13 days after vaccination.
CDC’s Advisory Committee on Immunization Practices (ACIP) will hold a meeting on Wednesday, April 14, 2021 to review the cases. FDA will then review the CDC analysis as a part of its investigation into the matter. “Until that process is complete, we are recommending a pause in the use of this vaccine out of an abundance of caution. This is important, in part, to ensure that the health care provider community is aware of the potential for these adverse events and can plan for proper recognition and management due to the unique treatment required with this type of blood clot,” FDA stated in a press release.
FDA’s decision to pause the use of the J&J vaccine is cautionary, stating the rarity of the adverse events. The agency recommends, however, that anyone who develop severe headache, abdominal pain, leg pain, or shortness of breath within three weeks of the J&J COVID-19 vaccination contact their health care provider.
Source: FDA
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
